share_log

Merck & Co | 8-K: Merck Announces Third-Quarter 2024 Financial Results

Merck & Co | 8-K: Merck Announces Third-Quarter 2024 Financial Results

默沙东 | 8-K：默沙东公布 2024 年第三季度财务业绩
美股SEC公告 ·  2024/10/31 11:46

Moomoo AI 已提取核心信息

Merck reported Q3 2024 total sales of $16.7 billion, up 4% YoY (7% ex-exchange), driven by strong KEYTRUDA performance with sales growing 17% to $7.4 billion. WINREVAIR launch gained momentum with $149 million in sales, while Animal Health revenue rose 6% to $1.5 billion.GAAP EPS was $1.24 and non-GAAP EPS was $1.57, both including a net charge of $0.79 per share related to business development transactions with EyeBio, Curon Biopharmaceutical, and Daiichi Sankyo. The quarter saw lower GARDASIL sales due to reduced China demand, though growth remained strong in other regions.For full-year 2024, Merck narrowed its sales guidance to $63.6-64.1 billion and revised non-GAAP EPS to $7.72-7.77, reflecting a $0.24 per share impact from recent business development deals. The company achieved significant milestones in vaccine programs, including CDC recommendation for CAPVAXIVE in adults 50+ and positive clinical data for its RSV antibody candidate.
Merck reported Q3 2024 total sales of $16.7 billion, up 4% YoY (7% ex-exchange), driven by strong KEYTRUDA performance with sales growing 17% to $7.4 billion. WINREVAIR launch gained momentum with $149 million in sales, while Animal Health revenue rose 6% to $1.5 billion.GAAP EPS was $1.24 and non-GAAP EPS was $1.57, both including a net charge of $0.79 per share related to business development transactions with EyeBio, Curon Biopharmaceutical, and Daiichi Sankyo. The quarter saw lower GARDASIL sales due to reduced China demand, though growth remained strong in other regions.For full-year 2024, Merck narrowed its sales guidance to $63.6-64.1 billion and revised non-GAAP EPS to $7.72-7.77, reflecting a $0.24 per share impact from recent business development deals. The company achieved significant milestones in vaccine programs, including CDC recommendation for CAPVAXIVE in adults 50+ and positive clinical data for its RSV antibody candidate.
默沙东报告2024年第三季度总销售额为167亿美元，同比增长4%（不考虑交易所影响增长7%），主要得益于KEYTRUDA表现强劲，销售额增长17%至74亿美元。WINREVAIR的发布势头增强，销售额达14900万美元，而动物健康营业收入增长6%至15亿美元。GAAP每股收益为1.24美元，非GAAP每股收益为1.57美元，均包括与EyeBio、Curon Biopharmaceutical和大冢制药的业务开发交易相关的每股净费用0.79美元。本季度由于中国需求减少，GARDASIL的销售有所下降，尽管其他地区的增长依然强劲。对于2024全年，默沙东缩小了销售指导至636-641亿美元，并将非GAAP每股收益修订为7.72-7.77美元，反映出最近的业务开发交易对每股的影响为0.24美元。该公司在生物-疫苗项目上取得了重大里程碑，包括CDC推荐CAPVAXIVE用于50岁以上成年人，以及其RSV抗体候选药物的积极临床数据。
默沙东报告2024年第三季度总销售额为167亿美元，同比增长4%（不考虑交易所影响增长7%），主要得益于KEYTRUDA表现强劲，销售额增长17%至74亿美元。WINREVAIR的发布势头增强，销售额达14900万美元，而动物健康营业收入增长6%至15亿美元。GAAP每股收益为1.24美元，非GAAP每股收益为1.57美元，均包括与EyeBio、Curon Biopharmaceutical和大冢制药的业务开发交易相关的每股净费用0.79美元。本季度由于中国需求减少，GARDASIL的销售有所下降，尽管其他地区的增长依然强劲。对于2024全年，默沙东缩小了销售指导至636-641亿美元，并将非GAAP每股收益修订为7.72-7.77美元，反映出最近的业务开发交易对每股的影响为0.24美元。该公司在生物-疫苗项目上取得了重大里程碑，包括CDC推荐CAPVAXIVE用于50岁以上成年人，以及其RSV抗体候选药物的积极临床数据。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Medicus Pharma
    MDCX
    -- 3.680
    Scilex Holding
    SCLX
    -- 0.354
    阿玛琳
    AMRN
    -- 0.612
    赛诺菲安万特
    SNY
    -- 54.500
    艾伯维公司
    ABBV
    -- 192.870
    解锁完整榜单
    热门讨论
    特朗普2.0时代开启，全球市场会如何演变？
    🎙️讨论： 1. 关税政策将如何影响美股、黄金、比特币等核心资产的走势？ 2. 在此背景下，有哪些投资机会值得关注？你会如何布局？ 展开
    MicroStrategy 2024年第四季度业绩电话会
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。